Johnson & Johnson and Boston Scientific have also recently made moves to sell their own coronary intravascular lithotripsy ...

Abbott will be trying its hand in the growing field of intravascular lithotripsy, with a clinical study to examine an unnamed ...

Abbott has announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) ...

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System to ...

Abbott ABT has received the FDA’s investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (“IVL”) system to evaluate the treatment of severe calcification in coronary ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Coronary Stents Market ...

The US Food and Drug Administration (FDA) has granted Abbott an investigational device exemption to evaluate the company’s ...

In the US, nearly two million stents are implanted every year, and they can be life-saving during a heart attack. But they may not always be the best treatment method for coronary artery disease.

Coronary Artery Disease (CAD) is the most common heart disease and most frequent ... potentially allowing for vessel expansion and better stent placement. Abbott's investigational Coronary IVL ...

The company says its investigational system uses high-energy sound pressure waves to treat calcium blockages and potentially allow for better stent placement. Abbott’s trial arrives in the wake ...

The stent keeps the ductus open after the baby is born, giving infants with heart conditions like Cayden’s the chance to receive better blood flow even when the heart itself can’t pump enough.